Forget Moderna: This Biotech Juggernaut Is Rising Fast
A biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
If overspending hit savings, concentrate on a concrete reset plan: set a short-term goal, cut a few costs, and automate a savings transfer to recover quickly.
24,735 articlesA biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
A profile of the country’s only full-time spelling bee coach, whose high hourly rate and prize-based bonuses are resh...
As SpaceX moves toward a historic public listing, Antonio Gracias could see his private stake surge into the tens of ...
The insurance backdrop is stabilizing in mid-2026, but homeowners coverage costs stay stubbornly high. Builders and l...
A hedge fund made a sizable Ultragenyx purchase as the stock slipped about 30% over the prior year. This article brea...
MicroStrategy disclosed its first Bitcoin sale under Michael Saylor’s strategy, selling 32 BTC to fund preferred stoc...
SPYI is delivering a near-12% yield year-to-date, but most distributions are classified as return of capital, which c...
What a difference a year makes. Last year, Wall Street questioned this AI stock’s valuation. Today, analysts anticipa...
A leading hedge fund investor says the current AI rally is fundamentally different from the late-1990s bubble, citing...
Ripple CEO Brad Garlinghouse signals a turning point as Wall Street embraces XRP-inspired infrastructure, marking a s...
Bitcoin edges toward a potential bottom as on-chain demand remains weak, signaling a fragile path to a durable recovery.
Traders worldwide can compete in a two-week sprint using Leveraged's Sprint accounts. The top performers will face of...